Nairobi, Sept. 9 -- The Pharmacy and Poisons Board (PPB) has begun reviewing an application to register Mounjaro, a booming once-weekly injectable diabetes drug, for use in Kenya.

The application was submitted by Aspen Pharmacare, a South African pharmaceutical company that has an agreement with Eli Lilly, the US manufacturer of Mounjaro, to distribute and promote the drug across sub-Saharan Africa.

PPB Chief Executive Ahmed Mohamed confirmed that the application was submitted and is currently at the screening stage, the first step in the regulatory review process.

"Yes, the PPB received an application to register Mounjaro in Kenya on May 7, 2026, and it's at the screening level," he told the Business Daily.

The regulator's review wil...